Vanda Pharmaceuticals’ (VNDA) “Sell (D-)” Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (d-) rating on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report published on Wednesday,Weiss Ratings reports.

A number of other equities analysts also recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Vanda Pharmaceuticals in a research note on Thursday, August 21st. Wall Street Zen downgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 2nd. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $16.50.

Vanda Pharmaceuticals Stock Down 2.6%

Shares of VNDA opened at $5.31 on Wednesday. The company’s fifty day moving average is $4.68 and its two-hundred day moving average is $4.55. Vanda Pharmaceuticals has a fifty-two week low of $3.81 and a fifty-two week high of $5.59. The firm has a market cap of $313.77 million, a PE ratio of -4.70 and a beta of 0.74.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.12). Vanda Pharmaceuticals had a negative net margin of 32.90% and a negative return on equity of 12.89%. The business had revenue of $52.59 million during the quarter, compared to analysts’ expectations of $54.77 million. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Vanda Pharmaceuticals will post -1.12 earnings per share for the current year.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nuveen LLC purchased a new stake in Vanda Pharmaceuticals during the 1st quarter worth $2,022,000. GSA Capital Partners LLP increased its position in shares of Vanda Pharmaceuticals by 88.0% in the 1st quarter. GSA Capital Partners LLP now owns 260,215 shares of the biopharmaceutical company’s stock worth $1,194,000 after purchasing an additional 121,797 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Vanda Pharmaceuticals in the 1st quarter worth about $875,000. XTX Topco Ltd increased its position in shares of Vanda Pharmaceuticals by 378.3% in the 1st quarter. XTX Topco Ltd now owns 69,329 shares of the biopharmaceutical company’s stock worth $318,000 after purchasing an additional 54,833 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Vanda Pharmaceuticals by 13.5% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 929,644 shares of the biopharmaceutical company’s stock worth $4,267,000 after purchasing an additional 110,262 shares during the last quarter. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.